2nd Annual Conference on Psychedelics and Psychedelic Medicine
We invite you to join us at the Westin Copley place in Boston for our 2nd Annual Conference on Psychedelics and Psychedelic Medicine conference. This conference will provide up-to-date overviews and discussions of advances in the field of psychedelics and psychedelic-assisted therapies, with an emphasis on clinical studies and practice. Mechanisms of action including pharmacology, neuroscience, psychodynamic theory will be discussed, with a focus on specific clinical entities such as depression, PTSD, an addictions. Additional panel discussions and presentations will explore history, ethics, cultural issues, plant medicine, and many other relevant topics within the rapidly growing field of psychedelic medicine.
Super Early Bird Registration (on or before August 26, 2022) $620.00
Early Bird Registration (on or before September 30, 2022) $650.00
Regular Registration (after September 30, 2022) $675.00
Other Professionals or Trainees
Super Early Bird Registration (on or before August 26, 2022) $525.00
Early Bird Registration (on or before September 30, 2022) $575.00
Regular Registration (after September 30, 2022) $620.00
Residents & Medical Students: $150.00
***The deeply discounted Super Early Bird Registration rate is NON-REFUNDABLE and NON-TRANSFERABLE and will not be refunded under any circumstances.
The conference syllabus is a printed book with all slide presentations and space to take notes adjacent to each slide.
Syllabus Book: $50
We provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference.
A refund minus a $100.00 administrative fee will be issued for refund requests received by October 30, 2022. No refunds will be issued for refund requests made after October 30, 2021. Payments made may not be applied to future conferences or other educational activities. There are no exceptions to these policies.
This program is intended for mental health practitioners including psychiatrists, psychiatric nurse practitioners, social workers and clinical psychologists.
By the end of this program, participants will be able to:
- Describe the history of psychedelic-assisted therapy within psychiatry, including aspects of medical and medico-cultural history
- Compare different models of psychedelic-assisted psychotherapy (eg, psycholytic vs psychedelic)
- List key psychiatric entities for which psychedelics have already shown promise, as well as specific studies in patient populations (such as for MDD)
- Explain the neuropsychopharmacology of classical psychedelics as well as atypical psychedelics such as ketamine and empathogens such as MDMA
- Apply contemporary neuroimaging research to understand key hypotheses for brain-based mechanisms of action of psychedelics in normal and clinical populations
- Explain research using psychedelic-assisted psychotherapy for depression and anxiety disorders
- Utilize existing evidence in the understanding of how psychedelics might be effective for the treatment of substance use disorders
- Identify hypotheses for mechanisms of action of psychedelics on the brain, based on recent neuroimaging studies
- Critique contemporary medico-cultural issues within psychedelic research, including race-based structural biases and epistemic injustice
- Describe challenges within training and education for the field of psychedelic-assisted therapy
- List and discuss potential risks of psychedelics, including risks of psychedelic-assisted therapy and challenges to accurately researching the effects of these therapies
- Assess potential applications of psychedelic-assisted therapy in extra-psychiatric fields, such as within palliative care and spirituality, as well as within medicine, such as for pain and immunomodulation
- Identify the role of plant medicines and how these understandings might inform next generations of treatments in 21st century medicine
2nd Annual Conference on Psychedelics and Psychedelic Medicine
November 4-5, 2022
Faculty to be announced soon!
Day 1 – November 4, 2022
Welcome and Introduction
8:05 – 8:25 AM
A Brief History of Psychedelics
Keynote: Psychedelic-Assisted Therapy: a 21st Century Approach to Mental Health?
Question & Answer
Psychedelics and Addictions
Psychedelic-Assisted Psychotherapy and Depression
MDMA-Assisted Therapy for PTSD
Using Cognitive Neuroscience To Advance Treatment with Psychedelics
Psychedelics and Autism Spectrum Disorder
Challenges in Trial Design for Psychedelic-Assisted Therapies
Risks of Psychedelics and Psychedelic Assisted Therapies
Ketamine and Esketamine for Major Depression
Ketamine-Assisted Psychotherapy – Inpatient Treatment of the Future?
Building an Outpatient Practice for Ketamine-Assisted Psychotherapy
Day 2 – November 5, 2022
Welcome & Introduction
Psychodynamics in Psychedelic-Assisted Psychotherapy
Challenging Structural Racism in Psychedelic Research
Education and Training in Psychedelic-Assisted Therapies
Ethics and Epistemic Injustice in Psychedelic Research
Psychedelic-Assisted Therapies in End-of-Life Care
Psychedelics and Spirituality
The Neurobiology of Plant Medicine: What Tradition Can Teach Us About Personalized Medicine
Potential Medical Applications of Psychedelics: Psychedelics and Inflammation
Psychedelics and Pain Disorders
Join us at the Westin Copley Place for the 2nd Annual Conference on Psychedelics and Psychedelic Medicine
We have arranged a special discounted rate for our valued attendees.
Please book by October 3, 2022 to enjoy this group rate.
Faculty will be announced soon!
Check back for CME information!
David H. Rubin, MD, reviewer
Jane Pimental, MPH
Susan E. Sprich, PhD, psychologist reviewer
Franklin King, MD
In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:
Susan Sprich, PhD (Psychologist Reviewer)
Royalties (Co-Author): Oxford University Press
Royalties (Co-Edited Book): Springer
Honoraria (Associate Editors): Association for Behavioral and Cognitive Therapies (ABCT)
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit